Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Low

Showing results (271-280 of 278) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 278 results.
Plos Biology|May 31, 2022
Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genesAyesa Syenina, Esther S Gan, Justin Z N Toh, et al.
EMBO Molecular Medicine|May 14, 2024
Electron transport chain capacity expands yellow fever vaccine immunogenicityDarren Zl Mok, Danny Jh Tng, Jia Xin Yee, et al.
NPJ Vaccines|December 13, 2022
A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccineJenny G Low, Ruklanthi de Alwis, Shiwei Chen, et al.
Nature Microbiology|January 10, 2025
Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humansShirin Kalimuddin, Christine Y L Tham, Yvonne F Z Chan, et al.
The Lancet. Infectious Diseases|June 1, 2014
Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trialJenny G Low, Cynthia Sung, Limin Wijaya, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 24, 2019
Oral vs Intravenous Antibiotics for Patients With Klebsiella pneumoniae Liver Abscess: A Randomized, Controlled Noninferiority StudyJames S Molton, Monica Chan, Shirin Kalimuddin, et al.
JAMA|March 4, 2020
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in SingaporeBarnaby Edward Young, Sean Wei Xiang Ong, Shirin Kalimuddin, et al.
Plos One|June 23, 2021
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodyConrad E Z Chan, Shirley G K Seah, De Hoe Chye, et al.
Pageof 28

Showing results (271-280 of 278) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 278 results.
Plos Biology|May 31, 2022
Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genesAyesa Syenina, Esther S Gan, Justin Z N Toh, et al.
EMBO Molecular Medicine|May 14, 2024
Electron transport chain capacity expands yellow fever vaccine immunogenicityDarren Zl Mok, Danny Jh Tng, Jia Xin Yee, et al.
NPJ Vaccines|December 13, 2022
A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccineJenny G Low, Ruklanthi de Alwis, Shiwei Chen, et al.
Nature Microbiology|January 10, 2025
Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humansShirin Kalimuddin, Christine Y L Tham, Yvonne F Z Chan, et al.
The Lancet. Infectious Diseases|June 1, 2014
Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trialJenny G Low, Cynthia Sung, Limin Wijaya, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 24, 2019
Oral vs Intravenous Antibiotics for Patients With Klebsiella pneumoniae Liver Abscess: A Randomized, Controlled Noninferiority StudyJames S Molton, Monica Chan, Shirin Kalimuddin, et al.
JAMA|March 4, 2020
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in SingaporeBarnaby Edward Young, Sean Wei Xiang Ong, Shirin Kalimuddin, et al.
Plos One|June 23, 2021
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodyConrad E Z Chan, Shirley G K Seah, De Hoe Chye, et al.
Pageof 28